Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical T1 Stage: A Multicenter Study in China

被引:11
|
作者
Liu, Ning [1 ]
Qu, Feng [1 ]
Shi, Qiancheng [1 ]
Zhuang, Wenyuan [1 ]
Ma, Wenliang [2 ]
Yang, Zhenhao [3 ]
Sun, Jing [4 ]
Xu, Wei [5 ]
Zhang, Lihua [6 ]
Jia, Ruipeng [7 ]
Xu, Linfeng [1 ]
Zhao, Xiaozhi [1 ]
Li, Xiaogong [1 ]
Zhang, Gutian [1 ]
Guo, Hongqian [1 ]
Li, Dongmei [8 ,9 ,10 ]
Gan, Weidong [1 ,2 ]
机构
[1] Nanjing Univ, Dept Urol, Nanjing Drum Tower Hosp, Med Sch,Affiliated Hosp, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Med Univ, Dept Urol, Drum Tower Clin Med Sch, Nanjing, Peoples R China
[3] Nanjing Univ Chinese Med, Dept Urol, Nanjing Drum Tower Hosp, Clin Coll Tradit Chinese & Western Med, Nanjing, Peoples R China
[4] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[5] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Canc Hosp, Dept Pathol, Nanjing, Peoples R China
[6] Southeast Univ, Zhongda Hosp, Dept Pathol, Nanjing, Peoples R China
[7] Nanjing Med Univ, Affiliated Nanjing Hosp, Nanjing Hosp 1, Dept Urol, Nanjing, Peoples R China
[8] Nanjing Univ, Med Sch, Immunol & Reprod Biol Lab, Nanjing, Peoples R China
[9] Nanjing Univ, State Key Lab Analyt Chem Life Sci, Med Sch, Nanjing, Peoples R China
[10] Nanjing Univ, Jiangsu Key Lab Mol Med, Nanjing, Peoples R China
基金
中国国家自然科学基金;
关键词
PARTIAL NEPHRECTOMY; TRANSITIONAL-CELL; GENE FUSIONS; TUMORS; FEATURES; ENTITY; SYSTEM; SCORE; TFE3; CLASSIFICATION;
D O I
10.1245/s10434-020-08813-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To evaluate the oncologic efficacy and feasibility of nephron-sparing surgery (NSS) in adult Xp11.2 translocation renal cell carcinoma (RCC). Patients and Methods Seventy patients with Xp11.2 translocation RCC and 273 with conventional RCC from five institutions in Nanjing were retrospectively studied. All patients were older than 18 years and were categorized into clinical T1 (cT1) stage using preoperative imaging. Using the preoperative imaging and electronic medical records, anatomical and pathological features were collected and analyzed. Results Among patients with Xp11.2 translocation RCC, 18/36 (50.0%) with cT1a and 12/34 (35.3%) with cT1b tumors underwent NSS. The respective proportions in the conventional RCC group were 121/145 (83.4%) and 93/128 (72.7%). Among cT1a tumors, the Xp11.2 translocation RCCs tended to be adjacent to the collecting system, sinus, and axial renal midline compared with conventional RCCs. Patients with Xp11.2 translocation RCCs who underwent NSS had comparable progression-free survival (PFS) and overall survival to radical nephrectomy (RN) patients (P > 0.05). Among cT1b tumors, surgical margin positivity and pelvicalyceal, vascular, and region lymphatic involvement were more likely to occur in the Xp11.2 translocation RCCs (P < 0.05). Patients with Xp11.2 translocation RCC who underwent RN had a more favorable PFS than those who underwent NSS (P = 0.048). However, multivariate analysis of PFS did not identify surgical method as a risk factor (P = 0.089). Conclusions Among adults with Xp11.2 translocation RCC, NSS can be an alternative for patients with cT1a tumor but should be performed with more deliberation in patients with cT1b tumors.
引用
收藏
页码:1238 / 1246
页数:9
相关论文
共 50 条
  • [1] Nephron-sparing surgery in the treatment of pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions
    Liu, Chao
    Zhang, Weiping
    Song, Hongcheng
    JOURNAL OF PEDIATRIC SURGERY, 2017, 52 (09) : 1492 - 1495
  • [2] Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib
    Solano, Cristian
    Thapa, Shrinjaya
    Chisti, Mohammad Muhsin
    BMJ CASE REPORTS, 2021, 14 (06)
  • [3] Renal Cell Carcinoma: Risks and Benefits of Nephron-Sparing Surgery for T1 Tumors
    Ghandour, Rashed A.
    Danzig, Matthew R.
    McKiernan, James M.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2015, 22 (04) : 258 - 265
  • [4] An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report
    Yu, Lu
    Li, Jun
    Xu, Sanpeng
    Miranda, Mariajose Navia
    Wang, Guoping
    Duan, Yaqi
    DIAGNOSTIC PATHOLOGY, 2016, 11
  • [5] Oncologic outcomes of nephron-sparing surgery in patients with T1 multifocal renal cell carcinoma
    Li, G.
    Zhu, D.
    Gao, H.
    Chen, H.
    Li, Y.
    Niu, Y.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (06): : 760 - 765
  • [6] XP11.2 Translocation renal cell carcinoma: Clinical experience of Taipei Veterans General Hospital
    Hung, Chia-Chen
    Pan, Chin-Chen
    Lin, Chih-Chieh
    Lin, Alex T. L.
    Chen, Kuang-Kuo
    Chang, Yen-Hwa
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2011, 74 (11) : 500 - 504
  • [7] Computed Tomography and Magnetic Resonance Imaging of Adult Renal Cell Carcinoma Associated With Xp11.2 Translocation
    Dang, Trien T.
    Ziv, Etay
    Weinstein, Stefanie
    Meng, Maxwell V.
    Wang, Zhen
    Coakley, Fergus V.
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2012, 36 (06) : 669 - 674
  • [8] Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion
    Wang, Zhen
    Liu, Ning
    Gan, Weidong
    Li, Xiaogong
    Zhang, Gutian
    Li, Dongmei
    Guo, Hongqian
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2017, 45 (04) : 1287 - 1296
  • [9] The Overall Survival Benefit for Patients with T1 Renal Cell Carcinoma after Nephron-Sparing Surgery Depends on Gender and Age
    Liek, Elisabeth
    Wunderlich, Heiko
    Elsebach, Klaus
    Goebel, Hubert
    Krah, Xaver
    Krautschick-Wilkens, Andreas W.
    Schweiger, Josef
    Steiner, Gabriel
    Steiner, Thomas
    Heinzelmann, Joana
    UROLOGIA INTERNATIONALIS, 2018, 100 (03) : 309 - 316
  • [10] Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers
    Park, Jee Soo
    Lee, Myung Eun
    Jang, Won Sik
    Kim, Jongchan
    Park, Se Mi
    Ham, Won Sik
    BIOMEDICINES, 2022, 10 (02)